Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TM5614 in combination with nivolumab for unresectable malignant melanoma
jRCT2021210029Phase 2Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Sep 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of TM5614 and nivolumab in melanoma, sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Response rate at 8 weeks after treatment start. Started Sep 2021; status: completed.
02
Drugs
TM5614nivolumab
03
Conditions
melanoma
Beyond the preview
Go deeper on jRCT2021210029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021210029.